Bristol-Myers Squibb Company Stock Quote & Summary Data
Dynamic quotes: Off
|
ETFs with BMY as a Top 10 Holding*Sponsored by:
| Weighting | ETF Name (Symbol) | 100-Day Price Change (%) |
|---|---|---|
| 6.49% | iShares Dow Jones U.S. Pharmaceutical Index Fund (IHE) | +16.07 (18.75%) |
| 5.26% | PowerShares Dynamic Pharmaceuticals (PJP) | +7.95 (22.80%) |
| 4.7% | Merrill Lynch Pharmaceutical HOLDRS (PPH) | +5.85 (14.17%) |
| 4.58% | SPDR S&P Pharmaceuticals ETF (XPH) | +12.66 (22.44%) |
| 3.89% | First Trust Morningstar Dividend Leaders Index Fund (FDL) | +3.10 (16.68%) |
|
||
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.
Company Description (as filed with the SEC)
Bristol-Myers Squibb Company (which may be referred to as Bristol-Myers Squibb, BMS, the Company, we, our or us) was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. We are engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Over the last few years, we executed our strategy to transform into a next generation biopharmaceutical company. This transformation encompassed all areas of our business and operations. As part of this strategy, we have divested our non-pharmaceutical businesses, implemented our acquisition and licensing strategy known as the “string-of-pearls”, and executed our productivity transformation initiative (PTI). ... More ...
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $1.99 |
| Quarterly EPS Est: | 0.45 |
| PEG Ratio: | 4.93 |
|
Mean Recommendation: View Summary / View All |
2.45 |
Data is provided by Zacks Investment Research